The preclinical evaluation of the 2-iodo-substituted somatostatin analog [68Ga]Ga-DOTA-ST8950 reveals its potential as PET tracer for in vivo imaging of SST2- and SST5-expressing tumors, which may be of interest for gastroenteropancreatic neuroendocrine tumors, pituitary tumors, and gastric cancers. Here, SSTR5 is linked to gastric cancer.